BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23722880)

  • 21. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
    Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
    Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of [
    Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
    Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.
    Whisenant JG; McIntyre JO; Peterson TE; Kang H; Sánchez V; Manning HC; Arteaga CL; Yankeelov TE
    Mol Imaging Biol; 2015 Feb; 17(1):119-28. PubMed ID: 25034624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
    Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
    J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arginine deprivation as a targeted therapy for cancer.
    Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
    Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
    Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
    Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.
    Benz MR; Czernin J; Allen-Auerbach MS; Dry SM; Sutthiruangwong P; Spick C; Radu C; Weber WA; Tap WD; Eilber FC
    Cancer; 2012 Jun; 118(12):3135-44. PubMed ID: 22020872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
    Shu XL; Liu XL; Zhong JX; Liu J
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2124-31. PubMed ID: 25070816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
    Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).
    Molthoff CF; Klabbers BM; Berkhof J; Felten JT; van Gelder M; Windhorst AD; Slotman BJ; Lammertsma AA
    Mol Imaging Biol; 2007; 9(6):340-7. PubMed ID: 17643202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 38. Applications of PET imaging with the proliferation marker [18F]-FLT.
    Peck M; Pollack HA; Friesen A; Muzi M; Shoner SC; Shankland EG; Fink JR; Armstrong JO; Link JM; Krohn KA
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):95-104. PubMed ID: 25737423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
    Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH
    Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.